A MULTICENTER, OPEN LABEL, PHARMACOKINETICS, PHARMACODYNAMICS AND SAFETY STUDY OF ELELYSO(TM) (TALIGLUCERASE ALFA) IN PEDIATRIC SUBJECTS WITH TYPE 1 GAUCHER DISEASE
Phase of Trial: Phase IV
Latest Information Update: 28 Dec 2018
At a glance
- Drugs Taliglucerase alfa (Primary)
- Indications Gaucher's disease type I
- Focus Pharmacokinetics
- Sponsors Pfizer
- 05 Sep 2018 Status changed from not yet recruiting to recruiting.
- 08 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Aug 2018.
- 03 Jul 2018 Planned initiation date changed from 1 Jun 2018 to 1 Jul 2018.